-- 据周四提交给澳大利亚证券交易所的文件显示,Tabcorp Holdings(ASX:TAH)表示,澳大利亚交易报告和分析中心(Austrac)对其管理洗钱和恐怖主义融资风险的能力提出了“严重”担忧,并已启动执法调查。 该公司表示,调查初期将重点评估其是否遵守《反洗钱和反恐怖主义融资法》(AML/CTF法案)规定的义务,包括是否拥有合规的AML/CTF计划、是否有效执行该计划以及是否对客户进行适当的监控。 该公司补充道,Austrac表示调查尚处于初期阶段,其调查策略将在收集和评估充分证据后确定,所有可能的结果均不排除,包括不采取进一步执法行动的可能性。 Tabcorp董事长Brett Chenoweth表示:“Tabcorp非常重视其反洗钱和反恐融资义务。董事会和管理层将全力配合澳大利亚交易报告和分析中心(Austrac),持续提升Tabcorp的反洗钱/反恐融资风险成熟度。” 该公司股价在上周四的交易中暴跌27%。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.